AstraZeneca
Organization
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. It develops and manufactures a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
What experts have said about AstraZeneca
8 statements · 3 positive · 4 negative · 1 neutral
AstraZeneca shares are currently depressed relative to their level since July.
“AstraZeneca shares are pretty depressed since July really”
Open the episode · AstraZeneca Climbs, Glencore Rises, Argenx SurgesListen at 1:41
AstraZeneca has become a cancer-drug powerhouse in recent years.
“it's become a cancer drug powerhouse under the CEO over the last few years”
Open the episode · AstraZeneca Plummets, Ryanair Rises, Clarkson JumpsListen at 1:45
AstraZeneca shares fell more than 7% that morning.
“AstraZeneca shares are actually down over 7% this morning.”
Open the episode · AstraZeneca Plummets, Ryanair Rises, Clarkson JumpsListen at 2:27
AstraZeneca reported higher-than-expected profit driven by cancer medications.
“reported higher than expected profit, boosted by its blockbuster cancer medications.”
Open the episode · Forte Bioscience Pop; Astrazeneca Reports; Paramount-Warner LatestListen at 1:58
AstraZeneca’s cancer-drug growth is offsetting pressures from lost exclusivity.
“their cancer drugs and the growth there is offsetting those pressures.”
Open the episode · AstraZeneca Climbs, Vodafone Gains, Pinewood SurgesListen at 3:52
AstraZeneca set a $5 billion sales target for the heart drug.
“Astra had set a $5 billion sales target for this drug.”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:21
The trial setback will make AstraZeneca’s $5 billion sales target harder to reach.
“this stumbling block is going to make it harder for the company to reach that deal”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:27
AstraZeneca’s trial setback may damage perceived credibility beyond lost revenue.
“some of this reaction might just be more than a loss of potential revenue but also a perceived slip in credibility”
Open the episode · Pepsi Reports; AstraZeneca and Levi Strauss FallListen at 2:37
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
15 episodes featuring AstraZeneca
Tomorrow, Today
Why strong projects still fail without human judgment
Organizations increasingly depend on projects to create future value, but plans and tools cannot compensate for weak sponsorship, unclear priorities, or political blind spots.
Aug 18, 2026 · 1h 51m
Stock Movers
European miners rise as drug trials reshape pharma stocks
The episode connects commodity prices, clinical-trial risk, and drone regulation to sharp moves across European and technology-linked companies.
Aug 17, 2026 · 6 min
Stock Movers
European shares split across drugs, copper and biotech
The episode shows how clinical setbacks, strategic access to copper and trial data can move major European stocks in sharply different directions.
Aug 17, 2026 · 6 min
Stock Movers
Tyson Foods lowers outlook while AstraZeneca eyes Bristol Myers Squibb merger
Major market shifts are colliding as agricultural inflation squeezes food production, biotech giants pursue massive consolidation, and aerospace enters a new public era.
Aug 3, 2026 · 7 min
Stock Movers
AstraZeneca weighs historic merger while chip stocks stage a recovery
This episode provides critical analysis of landmark shifts in global markets, from historic healthcare consolidation to the financial debut of commercial space flight.
Aug 3, 2026 · 6 min
Stock Movers
AstraZeneca plunges and BP divests as European markets undergo major shakeups
Understanding these major corporate realignments reveals how strategic shifts and geopolitical tensions are reshaping key European business sectors.
Aug 3, 2026 · 7 min
Stock Movers
AstraZeneca drops on merger talks while airlines and shipping surge
This episode highlights how shifting energy costs, geopolitical shipping disruptions, and aggressive cross-border healthcare deals are rapidly reshaping European equity markets.
Aug 3, 2026 · 7 min
The Sunday Roast
Mining deals and biotech catalysts shape a midsummer market review
The episode tests how financing, clinical evidence, national resilience and exploration milestones could reshape several small-cap stories through 2026.
Aug 2, 2026 · 1h 45m
Stock Movers
Argenx buys Forte Biosciences for billions as media merger talks stall
A multi-billion-dollar biotech buyout and regulatory roadblocks in media entertainment signal shifting strategies in corporate consolidation.
Jul 27, 2026 · 6 min
Stock Movers
Takeover bids and strong earnings push European stocks higher
This episode highlights the specific corporate catalysts driving European market gains, from private equity acquisitions to resilient telecom and pharmaceutical demand.
Jul 27, 2026 · 6 min
UK Small/Mid Caps with Paul Scott
Paul Scott makes the case for direct premium subscriptions
The episode is chiefly a subscriber note, clarifying how listeners can access premium content while separating personal investment opinions from financial advice.
Jul 10, 2026 · 32 min
Stock Movers
Micron bets big on US chipmaking as drug trial rattles AstraZeneca
The market moves reflect competing pressures on technology and healthcare companies: industrial investment and AI expectations on one side, clinical failure on the other.
Jul 9, 2026 · 5 min
Stock Movers
Drug trial failure jolts AstraZeneca as mixed earnings reshape market bets
The episode shows how company-specific surprises and sector-wide concerns can quickly outweigh otherwise solid results in premarket trading.
Jul 9, 2026 · 7 min
Stock Movers
European stocks split as drug, pharma and defense names diverge
The episode shows how clinical setbacks, revised company guidance and sector-wide pressure can send European shares in sharply different directions.
Jul 9, 2026 · 6 min
Stock Movers
Deutz bets on defense as AstraZeneca trial disappoints
The episode shows how European defense spending, biotech setbacks, and corporate earnings are pulling markets in sharply different directions.
Jul 9, 2026 · 7 min